
|Articles|January 14, 2009
Ipsen says FDA extending review date for Reloxin
Chicago - Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.
Advertisement
Chicago
- Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.
Ipsen also says the FDA confirmed the manufacturing process for the product in the Wales facility is in compliance, according to Reuters.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
3
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
4
Practical Approaches to Managing Atopic Dermatitis With Topical Therapies
5

















